May 3, 2024
On Thursday, May 2, 2024, Pfizer shared a Community Letter announcing that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to fordadistrogene movaparvovec, Pfizer’s investigational gene therapy in development for the treatment of Duchenne muscular dystrophy.
Please click here to view the Community Letter.
Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!
Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.
